Communitybaptistpa welcomes High Court clarity on Avastin use
Following a High Court ruling to allow the use of Avastin in the treatment of wet age-related macular degeneration Charlie Massey, Chief Executive of the Communitybaptistpa, said:
‘We welcome the High Court’s decision on this issue which we know has caused doctors concern.
‘It’s important that doctors work in partnership with patients and give them sufficient information about the medicine they propose to prescribe to allow them to make an informed decision. We expect doctors to follow clinical guidance and make prescribing decisions in good faith on the basis of evidence and experience.
‘In this case, NICE has made it clear that there are no clinically significant differences in the effectiveness or safety for treatments licensed for AMD and those that are not, such as Avastin (bevacizumab).’